ReviewBiomolecules2026
Research Progress in Biomedical Materials.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Biomedical materials, which are engineered to interact safely and effectively with biological systems, serve as the foundation of modern medicine. They facilitate precise diagnostics, targeted therapies, tissue regeneration, and the functional restoration of damaged organs and tissues. Propelled by advancements in materials science, nanotechnology, and clinical understanding, this field is rapidly evolving from passive implants to intelligent, responsive, and bioactive systems. This review summarize recent breakthroughs in four crucial domains: hard-tissue repair, dynamic wound healing, spatiotemporally controlled drug delivery, and advanced surface engineering. This article rigorously assesses the persistent translational barriers, particularly the disparity between in vitro biocompatibility assays and clinical performance, the scalability constraints in manufacturing, and the fragmentation in regulatory frameworks and international standards. By connecting fundamental innovation with real-world clinical needs, this review functions as both a strategic reference for researchers and a practical resource for clinicians exploring the next generation of biomedical materials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.